PHOSPHOLIPIDS IN MYOCARDIAL ISCHEMIC REPERFUSION INJURY
Project Number2R01HL034360-13
Contact PI/Project LeaderDAS, DIPAK K
Awardee OrganizationUNIVERSITY OF CONNECTICUT SCH OF MED/DNT
Description
Abstract Text
DESCRIPTION (provided by applicant): The application proposes to continue
examining the signal transduction processes transmitting death signal to the
cardiomyocytes during myocardial ischemia and reperfusion. During the current
years' funding, our laboratory locumented the invo'vement of 'MAP kinase
signaling in the development of ischemic reperfusion injury, and more
importantly in the process of myocardial adaptation to ischemic stress. The MAP
kinase signaling was found to modulate the death signal by reprogramming of
gene expression. A number of redox-regulated transcription factors and genes
were found to be involved in the signaling cascade leading to cardiomyocyte
death due to necrosis and apoptosis.
The proposed research will further explore the regulation of death and survival
signals of MAP kinase cascades by addressing the following Specific Aims: i) by
studying Src kinase regulation of cardiomyocyte life and death and its relation
to the downstream kinases p38MAPK, JNK and ERK as well as by determining the
role of tyrosine phosphorylation of PLCy; ii) by examining PI-3-kinase-Akt
signaling in transmitting survival signal during ischemia/reperfusion and
ischemic adaptation; iii) by studying the significance of JAKJSTAT signaling in
ischemic reperfusion injury and following the death signal through caspase
activation; iv) by examining the regulation of the transcription factors and
induction of gene expression that modulate the death and/or survival signal as
well as by studying transcription regulation of downstream kinases, p38MAPK and
ERK and JNK by some of these genes; and v) by examining the second messenger
role of reactive oxygen species in MAP kinase signaling and their transcription
regulation. The experimental models will involve both working and Langendorif
rat and mouse hearts, genetically engineered mouse, isolated cardiomyocytes,
antisense gene delivery and dominant negative cells. The studies will include
determination of the key signaling members of MAP kinase pathway both at mRNA
and protein levels, their post-translational modification and transcription
regulation by transcription factors and/or genes responsible for transmitting
death and/or survival signal, and evaluation of cardiomyocyte apoptosis by
study its progression through cytochrome c release and caspase activation. The
overall objective is to delineate the signal transduction processes responsible
for transmitting death signal and to explore interventions that change the
death signal into survival signal which would lead to developing therapeutic
modalities to reduce cardiomyocyte death due to apoptosis and necrosis.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
JUN kinase apoptosis biological signal transduction cardiac myocytes cell death cysteine endopeptidases cytochrome c enzyme activity enzyme induction /repression free radical oxygen genetically modified animals laboratory mouse laboratory rat lipid transport mitogen activated protein kinase myocardial ischemia /hypoxia oxidative stress phosphatidylinositol 3 kinase phospholipids protein protein interaction protein tyrosine kinase reperfusion transcription factor
No Sub Projects information available for 2R01HL034360-13
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01HL034360-13
Patents
No Patents information available for 2R01HL034360-13
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01HL034360-13
Clinical Studies
No Clinical Studies information available for 2R01HL034360-13
News and More
Related News Releases
No news release information available for 2R01HL034360-13
History
No Historical information available for 2R01HL034360-13
Similar Projects
No Similar Projects information available for 2R01HL034360-13